MCF Advisors LLC Has $49,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

MCF Advisors LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 5,850.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 476 shares of the company’s stock after acquiring an additional 468 shares during the quarter. MCF Advisors LLC’s holdings in Novo Nordisk A/S were worth $49,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of NVO. International Assets Investment Management LLC boosted its position in Novo Nordisk A/S by 133.2% during the 3rd quarter. International Assets Investment Management LLC now owns 7,837 shares of the company’s stock worth $719,000 after acquiring an additional 4,476 shares during the last quarter. AE Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 142.8% in the 3rd quarter. AE Wealth Management LLC now owns 26,888 shares of the company’s stock valued at $2,445,000 after buying an additional 15,812 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of Novo Nordisk A/S by 61.6% in the 3rd quarter. IFP Advisors Inc now owns 4,244 shares of the company’s stock valued at $386,000 after buying an additional 1,618 shares during the last quarter. Arkadios Wealth Advisors boosted its holdings in shares of Novo Nordisk A/S by 99.5% in the 3rd quarter. Arkadios Wealth Advisors now owns 3,671 shares of the company’s stock valued at $334,000 after buying an additional 1,831 shares during the last quarter. Finally, RFG Advisory LLC boosted its holdings in shares of Novo Nordisk A/S by 90.1% in the 3rd quarter. RFG Advisory LLC now owns 7,039 shares of the company’s stock valued at $640,000 after buying an additional 3,336 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1 %

Shares of Novo Nordisk A/S stock opened at $125.23 on Tuesday. The business has a fifty day simple moving average of $126.49 and a two-hundred day simple moving average of $111.28. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The company has a market capitalization of $561.97 billion, a price-to-earnings ratio of 46.30, a P/E/G ratio of 2.05 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Research analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent analyst reports. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.